These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 12132996)

  • 1. Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design.
    Brömme D; Kaleta J
    Curr Pharm Des; 2002; 8(18):1639-58. PubMed ID: 12132996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging roles of cysteine cathepsins in disease and their potential as drug targets.
    Vasiljeva O; Reinheckel T; Peters C; Turk D; Turk V; Turk B
    Curr Pharm Des; 2007; 13(4):387-403. PubMed ID: 17311556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of synthetic acridones and 4-quinolinones as potent inhibitors of cathepsins L and V.
    Marques EF; Bueno MA; Duarte PD; Silva LR; Martinelli AM; dos Santos CY; Severino RP; Brömme D; Vieira PC; Corrêa AG
    Eur J Med Chem; 2012 Aug; 54():10-21. PubMed ID: 22591648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.
    Yasuda Y; Kaleta J; Brömme D
    Adv Drug Deliv Rev; 2005 May; 57(7):973-93. PubMed ID: 15876399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships of hypervalent organochalcogenanes as inhibitors of cysteine cathepsins V and S.
    Piovan L; Alves MF; Juliano L; Brömme D; Cunha RL; Andrade LH
    Bioorg Med Chem; 2011 Mar; 19(6):2009-14. PubMed ID: 21345684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of nitrile-based peptidic inhibitors of cysteine cathepsins.
    Frizler M; Stirnberg M; Sisay MT; Gütschow M
    Curr Top Med Chem; 2010; 10(3):294-322. PubMed ID: 20166952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substrate-derived triazolo- and azapeptides as inhibitors of cathepsins K and S.
    Galibert M; Wartenberg M; Lecaille F; Saidi A; Mavel S; Joulin-Giet A; Korkmaz B; Brömme D; Aucagne V; Delmas AF; Lalmanach G
    Eur J Med Chem; 2018 Jan; 144():201-210. PubMed ID: 29272750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells.
    Wilder CL; Walton C; Watson V; Stewart FAA; Johnson J; Peyton SR; Payne CK; Odero-Marah V; Platt MO
    Int J Biochem Cell Biol; 2016 Oct; 79():199-208. PubMed ID: 27592448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
    Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
    J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based development of specific inhibitors for individual cathepsins and their medical applications.
    Katunuma N
    Proc Jpn Acad Ser B Phys Biol Sci; 2011; 87(2):29-39. PubMed ID: 21321479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cysteine cathepsin S as an immunomodulatory target: present and future trends.
    Gupta S; Singh RK; Dastidar S; Ray A
    Expert Opin Ther Targets; 2008 Mar; 12(3):291-9. PubMed ID: 18269339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct properties of prohormone thiol protease (PTP) compared to cathepsins B, L, and H: evidence for PTP as a novel cysteine protease.
    Azaryan AV; Hook VY
    Arch Biochem Biophys; 1994 Oct; 314(1):171-7. PubMed ID: 7944391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods for computer-aided chemical biology. Part 5: rationalizing the selectivity of cathepsin inhibitors on the basis of molecular fragments and topological feature distributions.
    Ahmed HE; Bajorath J
    Chem Biol Drug Des; 2009 Aug; 74(2):129-41. PubMed ID: 19549075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Future of Cysteine Cathepsins in Disease Management.
    Kramer L; Turk D; Turk B
    Trends Pharmacol Sci; 2017 Oct; 38(10):873-898. PubMed ID: 28668224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysosomal cysteine proteases (cathepsins): promising drug targets.
    Turk D; Guncar G
    Acta Crystallogr D Biol Crystallogr; 2003 Feb; 59(Pt 2):203-13. PubMed ID: 12554931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice.
    Xiang A; Kanematsu M; Kumar S; Yamashita D; Kaise T; Kikkawa H; Asano S; Kinoshita M
    Bone; 2007 May; 40(5):1231-7. PubMed ID: 17347064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators.
    Turk B; Turk D; Salvesen GS
    Curr Pharm Des; 2002; 8(18):1623-37. PubMed ID: 12132995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irreversible inhibition of human cathepsins B, L, S and K by hypervalent tellurium compounds.
    Cunha RL; Gouvêa IE; Feitosa GP; Alves MF; Brömme D; Comasseto JV; Tersariol IL; Juliano L
    Biol Chem; 2009 Nov; 390(11):1205-12. PubMed ID: 19663682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production and activation of recombinant papain-like cysteine proteases.
    Brömme D; Nallaseth FS; Turk B
    Methods; 2004 Feb; 32(2):199-206. PubMed ID: 14698633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors.
    Katunuma N; Matsunaga Y; Himeno K; Hayashi Y
    Biol Chem; 2003 Jun; 384(6):883-90. PubMed ID: 12887055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.